Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
about
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organsDiscovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.L-Proline catalyzed one-step synthesis of 4,5-diaryl-2H-1,2,3-triazoles from heteroaryl cyanostilbenes via [3+2] cycloaddition of azide.The biology of the combretastatins as tumour vascular targeting agents.Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents.Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agentsSynthesis and antitumor molecular mechanism of agents based on amino 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan: inhibition of tubulin and induction of apoptosis.2-[(4-Formyl-phen-yl)(hy-droxy)meth-yl]acrylonitrile.Synthesis of phenstatin/isocombretastatin-chalcone conjugates as potent tubulin polymerization inhibitors and mitochondrial apoptotic inducers.(Z)-3-(1H-Indol-3-yl)-2-(3,4,5-tri-methoxy-phen-yl)acrylonitrile(Z)-3-(1-Benzofuran-2-yl)-2-(3,4,5-tri-meth-oxy-phen-yl)acrylonitrile.Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin.Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity.2-[Hy-droxy(2-meth-oxy-phenyl)methyl]acrylonitrileRoute to α-Aryl Phosphonoacetates: Useful Synthetic Precursors in the Horner-Wadsworth-Emmons Olefination.Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization2-[(2-Chloro-quinolin-3-yl)(hy-droxy)meth-yl]acrylo-nitrile.Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agentsHighly potent triazole-based tubulin polymerization inhibitors.Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity.Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006)Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.Synthesis and Evaluation of Millepachine Amino Acid Prodrugs With Enhanced Solubility as Antitumor Agents.Application of Suzuki arylation, Sonogashira ethynylation and Rosenmund-von Braun cyanation in the exploration of substitution effects on the anticancer activity of 2-aroylquinolines.Combretastatin A-4 derivatives: synthesis and evaluation of 2,4,5-triaryl-1H-imidazoles as potential agents against H1299 (non-small cell lung cancer cell).B-ring-modified isocombretastatin A-4 analogues endowed with interesting anticancer activities.The metabolic fate of isocombretastatin A-4 in human liver microsomes: identification, synthesis and biological evaluation of metabolites.Concise syntheses of N-aryl-5,6,7-trimethoxyindoles as antimitotic and vascular disrupting agents: application of the copper-mediated Ullmann-type arylation.Discovery of isoerianin analogues as promising anticancer agents.Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.CuI/1,10-phen/PEG promoted decarboxylation of 2,3-diarylacrylic acids: synthesis of stilbenes under neutral and microwave conditions with an in situ generated recyclable catalyst.Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth.Computational Design and Synthesis of Novel Fluoro-Analogs of Combretastatins A-4 and A-1.Synthesis and evaluation of bile acid amides of [Formula: see text]-cyanostilbenes as anticancer agents.Tumor environment changed by combretastatin derivative (Cderiv) pretreatment that leads to effective tumor targeting, MRI studies, and antitumor activity of polymeric micelle carrier systems.The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy.
P2860
Q24651931-00A62BE6-5C7A-492A-85E4-64ADBF426043Q31024172-4603F813-ABDC-489A-9516-56410E97BB03Q33879273-5A22117E-CDE3-45E1-82CE-BA77D55BEB23Q34247101-46B669C5-1E78-42C4-BB0A-A1C510907A53Q34680614-CA96C812-9BD1-44A0-86CA-77B3495170B8Q34955360-5C5DD88D-6843-4445-BC64-8EB1CBE07BC2Q35108206-A33DD233-58BA-4634-B4C2-73B9DD0DA7FEQ35309200-8674BB4D-D935-436D-8B1E-D963B96C6C6EQ35542592-822F0478-AD4A-49B0-B490-65002758AE9EQ35568576-D3889E72-045C-4726-BBFD-083D4E4EC943Q35808247-4318A255-DD8E-4209-BD43-5D70CC694D50Q35808257-2F006D54-3C28-49E6-B1A9-0F6D434E8AC3Q35924307-1CF038BB-61FD-4017-B92C-8E3AD4BAD8DAQ36016221-C0BE1F8F-B35A-493C-BBAA-1ABC15BC6CC2Q36150938-C126319D-0A2F-46F0-A62C-8398F02D7B53Q36182529-BA86DE24-E15C-4347-AB4C-0B4BD7EA685EQ36788673-B1185EEE-62C7-4E1F-ADC5-5F98CA24D85FQ36827756-11A71102-6101-43A1-A525-95C3F4838A2CQ36839418-710449D3-05FF-442D-830A-46A0467F34A6Q37222445-9ABA1A56-3E5D-4F40-8E3B-BF5216B6CE7BQ37342450-798C1029-80DF-4561-8B60-973A2B10BD01Q37626788-A51B8F56-A161-48A3-8597-2153F7A7C383Q37670789-DD9ACC5A-510E-40CD-8BD8-FF994BE787FDQ38602109-958D424A-E6FB-4FC0-991F-83C5B825EA9FQ38913969-50F1CD00-CE4C-4DF0-B19F-2D406B3865C2Q39248597-8997EAE9-D7DA-4738-ACF6-47C0566C2773Q39271612-17070866-3B2F-4159-8A68-27D2A4A5FB42Q39459714-DFD893D4-03DC-4703-80A1-AA17D7567723Q39508272-5A896BA2-C71E-4871-8E19-06999BE60818Q39574351-CA6B76FB-88DE-4FD7-BE85-BFDCF85F80D3Q39584180-5857EB81-E67D-4BA0-BD83-E3DD4959DC5CQ44412196-DD06742B-E96E-44F0-96D2-1A2A7F25D5D5Q44864691-681134BD-2D64-46BA-B193-74952F6FEA73Q46614854-5582534D-93D2-4623-B6E1-81907AED0A29Q47726553-0EE564A9-0D45-47D9-8DF7-0993E568EDE2Q49853465-3EE834CA-CD3F-4705-9705-2F7823D90F38Q52614294-155156B0-FA4B-478E-9864-78F3E0808E23Q52627703-C71F4B05-2F62-4DEA-B1A0-2AC6054428F9Q52769257-A79CB862-7676-46A1-8AC6-E558FBB56865Q55031551-E7FA3360-5EF0-4E7C-A9A1-D01FE4979902
P2860
Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Novel combretastatin analogues ...... ucture-activity relationships.
@en
Novel combretastatin analogues ...... ucture-activity relationships.
@nl
type
label
Novel combretastatin analogues ...... ucture-activity relationships.
@en
Novel combretastatin analogues ...... ucture-activity relationships.
@nl
prefLabel
Novel combretastatin analogues ...... ucture-activity relationships.
@en
Novel combretastatin analogues ...... ucture-activity relationships.
@nl
P2093
P356
P1476
Novel combretastatin analogues ...... ucture-activity relationships.
@en
P2093
Hatanaka T
Morinaga Y
Nakagawa R
P304
P356
10.1021/JM980101W
P407
P577
1998-07-01T00:00:00Z